Would You Bet on a $1.50 Biotech Stock?

Editas Medicine’s stock has crashed 97% and now trades for about $1.50, but some Wall Street folks think it could double. The catch? Their main gene-editing treatment fizzled out because it was too complicated and pricey, plus rivals beat them to market. Now they’re pivoting to a new approach, but it’s super early days—think lottery ticket, not sure thing. If you’re feeling lucky, maybe grab a coffee and watch this one from the sidelines! #investing #biotech #stocks #Business